Journal of Dermatological Treatment · 2024 · 12 citations · 6 references
MedicineDermatologyPharmacotherapyAllergyClinical PharmacologyHypersensitivityAtopic DermatitisContact DermatitisAtopic Dermatitis PharmacotherapyAtopic Dermatitis TreatmentDisease Severity IndexJak Inhibitor TherapyJak InhibitorsNumerical Rating ScalesSafety Profile CharacterizationSeverity Index Measurement
Aim: Abrocitinib is a JAK-1 inhibitor approved for the treatment of moderate-to-severe atopic dermatitis (AD). We conducted a 16-week multicenter retrospective study to assess the short-term effectiveness and safety of abrocitinib in patients with moderate-to-severe AD.Our retrospective study included 85 adult patients from 14 Italian Dermatology Units affected by moderate-to-severe AD treated with abrocitinib 100/200 mg.Methods: Effectiveness of abrocitinib at weeks 4 and 16 was assessed by using the Eczema Area and Severity Index (EASI), the Investigator Global Assessment (IGA), the peak pruritus and sleep- Numerical Rating Scale (PP-NRS and S-NRS, respectively).Results: At week 16, improvement of at least 90% in EASI (EASI90) and IGA 0/1 was observed in 49.4% and 61.2% of patients, respectively. A reduction of at least 4 points in PP-NRS and S-NRS compared with baseline was achieved by 70.6% of patients for both endpoints. No significant safety reports were observed during the study period. Naïve patients had better rates of EASI 90 compared to patients who previously failed dupilumab.Conclusion: Our data confirm the effectiveness of abrocitinib in a real-world setting with better clinical responses at weeks 4 and 16, compared with Phase-III clinical trials. Longer analyses are required to further establish the safety profile of abrocitinib.
6
Eric L. Simpson, Rodney Sinclair, Seth Forman et al. · The Lancet · 2020 · 491 citations · Full text
Medicine, Dermatology, Immunology +14
Jill I. Olydam, Anne R. Schlösser, Paolo Custurone et al. · Journal of the European Academy of Dermatology and Venereology · 2023 · 40 citations · Full text
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli et al. · Dermatology and Therapy · 2024 · 34 citations · Full text
Medicine, Dermatology, Pharmacology +14
Eric L. Simpson, Jonathan I. Silverberg, Jacob P. Thyssen et al. · American Journal of Clinical Dermatology · 2023 · 27 citations · Full text